Sirolimus (rapamycin)-based therapy in human renal transplantation -: Similar efficacy and different toxicity compared with cyclosporine

被引:727
|
作者
Groth, CG [12 ]
Bäckman, L
Morales, JM
Calne, R
Kreis, H
Lang, P
Touraine, JL
Claesson, K
Campistol, JM
Durand, D
Wramner, L
Brattström, C
Charpentier, B
机构
[1] Karolinska Inst, Huddinge Hosp, S-10401 Stockholm, Sweden
[2] Sahlgrens Univ Hosp, S-41345 Gothenburg, Sweden
[3] Hosp 12 Octubre, E-28041 Madrid, Spain
[4] Addenbrookes Hosp, Cambridge, England
[5] Hop Necker Enfants Malad, Paris, France
[6] Hop Henri Mondor, F-94010 Creteil, France
[7] Hop Edouard Herriot, Lyon, France
[8] Univ Uppsala Hosp, Uppsala, Sweden
[9] Hosp Clin Barcelona, Barcelona, Spain
[10] Univ Hosp Rangueil, Toulouse, France
[11] Hop Bicetre, Kremlin Bicetre, France
[12] Huddinge Hosp, Dept Transplant Surg, S-14186 Huddinge, Sweden
关键词
D O I
10.1097/00007890-199904150-00017
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Sirolimus (rapamycin) is a potent immunosuppressant with a mechanism of action different from cyclosporine (CsA) or tacrolimus. Methods. In 11 European centers, first cadaveric renal allograft recipients were randomized to CsA (n=42) or sirolimus (n=41). Dosing of these agents was concentration-controlled and open-labeled. All patients received corticosteroids and azathioprine. Results. At 12 months, graft survival (98% sirolimus vs. 90% CsA), patient survival (100% vs. 98%), and incidence of biopsy-confirmed acute rejection (41% vs. 38%) were similar, Serum creatinine was lower with sirolimus, significantly (P less than or equal to 0.05) so at 3 and 4 months, and serum uric acid and magnesium were normal. Laboratory abnormalities reported significantly more often with sirolimus included hypertriglyceridemia (51% vs. 12%), hypercholesterolemia (44% vs. 14%), thrombocytopenia (37% vs, 0%), leukopenia (39% vs. 14%), and, of lesser importance, increased liver enzymes and hypokalemia. These abnormalities improved 2 months after transplantation when the sirolimus target trough level was lowered from 30 to 15 ng/ml. Occurrence of cytomegalovirus was comparable (14% vs. 12%); incidences of herpes simplex (24% vs. 10%, P=0.08) and pneumonia (17% vs. 2%, P=0.03) were higher with sirolimus. No gingival hyperplasia was seen with sirolimus, tremor was rare, and hypertension was less frequent (17% vs. 33%), Two malignancies were observed with CsA and none with sirolimus. Conclusions. Results at 12 months suggest that sirolimus can be used as base therapy in the prophylaxis of acute renal transplant rejection, and has a safety profile that differs from CsA.
引用
收藏
页码:1036 / 1042
页数:7
相关论文
共 50 条
  • [41] Postmarketing evaluation of mycophenolate mofetil-based triple therapy immunosuppression compared with a conventional azathioprine-based regimen reveals enhanced efficacy and early pharmacoeconomic benefit after renal transplantation
    Wüthrich, RP
    Weinreich, T
    Schwarzkopf, AK
    Candinas, D
    Binswanger, U
    TRANSPLANTATION PROCEEDINGS, 1998, 30 (08) : 4096 - 4097
  • [42] Determining Renal Resistive and Pulsatility Indexes Long-Term After Kidney Transplantation in Kidney Transplant Recipients on Cyclosporine A-, Tacrolimus-, or Sirolimus-Based Regimens
    Boran, M.
    Tola, M.
    Boran, M.
    Boran, E.
    Gonenc, F.
    TRANSPLANTATION PROCEEDINGS, 2014, 46 (05) : 1324 - 1327
  • [43] Sirolimus/steroids Maintenance Therapy after Early Cyclosporine Withdrawal: 12-month Efficacy and Safety Results of Multicenter Single Arm Pilot Study in Primary Renal Allograft Recipients in Korea
    Ju, Man Ki
    Han, Duck-Jong
    Kim, Soo Jin
    Moon, In Sung
    Kim, Yong Lim
    Kim, Hyun Chul
    Kim, Seong Joo
    Kim, Sang Joon
    Kim, Soon Il
    Kim, Yeong Hoon
    Oh, Chang Kwon
    Kim, Yu Seun
    JOURNAL OF THE KOREAN SURGICAL SOCIETY, 2010, 79 (04): : 261 - 266
  • [44] Assessment of efficacy and renal toxicity of pre-emptive therapy for CMV reactivation in paediatric patients who underwent allogeneic stem cell transplantation
    Cesaro, S
    Calò, A
    Pillon, M
    Tridello, G
    Varotto, S
    Calore, E
    Mengoli, C
    Cusinato, R
    Messina, C
    BONE MARROW TRANSPLANTATION, 2006, 37 : S170 - S170
  • [45] Comparison of a delayed low-dose sirolimus(Siro)/Mycophenolate mofetil (MMF)-based therapy with standard cyclosporine (CSA)/MMF-based immunosuppression in patients after kidney transplantation (smart-study)
    Guba, Markus
    Pratschke, Johann
    Hugo, Christian
    Kraemer, Bernhard
    Burmeister, Dirk
    Brockmann, Jens
    Jauch, Karl-Walter
    TRANSPLANT INTERNATIONAL, 2007, 20 : 141 - 141
  • [46] Conversion to sirolimus-based therapy to achieve calcinurin-inhibitor-free and steroid-free immuno-suppression in renal transplantation: A single unit experience
    Sharma, Ajay K.
    Murphy, John
    Kumar, Avneesh
    Smith, Jane
    Bakran, Ali
    Rustom, Rana
    Hammad, Abdel
    Howse, Mathew
    TRANSPLANT INTERNATIONAL, 2007, 20 : 137 - 137
  • [47] A randomized prospective trial of daclizumab induction followed by sirolimus in association with mycophenolate mofetil and steroids versus standard cyclosporin based triple therapy for rejection prophylaxis in renal transplantation
    Riad, Hany
    Tavakoli, Afshin
    Hamer, Clare
    Augustine, Titus
    Parrott, Neil
    Nimako, Louise
    Sharma, Ajay
    Hammad, Abdul
    TRANSPLANT INTERNATIONAL, 2007, 20 : 116 - 116
  • [48] Efficacy and Optimised Dosing in Tacrolimus Prolonged Release vs Tacrolimus Immediate Release-Based Therapy in Renal Transplantation - The OSAKA Study
    Albano, L.
    Banas, B.
    Rostaing, L.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 125 - 125
  • [49] Combined immunosuppression with cyclosporine (Neoral) and SDZ RAD in non-human primate lung transplantation: Systematic pharmacokinetic-based trials to improve efficacy and tolerability
    Hausen, B
    Ikonen, T
    Briffa, N
    Berry, GJ
    Christians, U
    Robbins, RC
    Hook, L
    Serkova, N
    Benet, LZ
    Schuler, W
    Morris, RE
    TRANSPLANTATION, 2000, 69 (01) : 76 - 86
  • [50] EFFICACY, SAFETY AND OPTIMISED DOSING IN TACROLIMUS PROLONGED RELEASE VS TACROLIMUS IMMEDIATE RELEASE-BASED THERAPY IN RENAL TRANSPLANTATION - THE OSAKA STUDY
    Banas, B.
    Boeger, C. A.
    Lehner, F.
    TRANSPLANT INTERNATIONAL, 2011, 24 : 35 - 35